TY - JOUR T1 - Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01778-2017 VL - 51 IS - 3 SP - 1701778 AU - Scott K. Heysell AU - Shahriar Ahmed AU - Md. Toufiq Rahman AU - Md. Wahiduzzaman Akhanda AU - A. Tucker Gleason AU - Andrew Ebers AU - Eric R. Houpt AU - Sayera Banu Y1 - 2018/03/01 UR - http://erj.ersjournals.com/content/51/3/1701778.abstract N2 - World Health Organization (WHO) recommendations for multidrug-resistant tuberculosis (MDR-TB) include treatment for 8 months or more of an aminoglycoside, such as kanamycin, amikacin or capreomycin, or a shorter course of 4 months or more, depending on the susceptibility of the patient's Mycobacterium tuberculosis isolate to other drugs in the regimen [1]. Aminoglycosides can produce significant side-effects, including irreversible ototoxicity, estimated to occur in 25–60% of patients treated for MDR-TB, depending on methods of measurement [2–5]. Even if surviving to cure, MDR-TB treatment itself is impoverishing [6], while ototoxicity further limits a patient's ability to regain employment and may compound social isolation.High frequency hearing loss from kanamycin in MDR-TB treatment: not if, but when? http://ow.ly/dLQb30hPD2dicddr,b acknowledges with gratitude the commitment of the National Institutes of Health to its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. The authors also express their sincere gratitude to the authority of NIDCH for their continued support to the studies conducted by icddr,b. ER -